Contact
searchSearch
HMP Global
Login

CAR-T Therapies

Featured

News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
News
High Tumor Mutational Burden Predicts CAR-T Outcomes in LBCL, ASH 2025 Study Finds
12/05/2025
Juliet Gallagher
A new analysis presented at ASH 2025 identifies high tumor mutational burden as a clinically meaningful biomarker of negative outcomes following CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL). Using...
A new analysis presented at ASH 2025 identifies high tumor mutational burden as a clinically meaningful biomarker of negative outcomes following CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL). Using...
A new analysis presented at ASH...
12/05/2025
Journal of Clinical Pathways
News
Expanding Access to CAR T-Cell Therapy Through Early Referral and Broader Eligibility
11/14/2025
Lisa Kuhns, PhD, MD
A panel of experts determined that early referral for chimeric antigen receptor (CAR) T-cell therapy, ideally at relapse and before the next treatment line, can expand access and improve outcomes, as multidisciplinary collaboration makes this...
A panel of experts determined that early referral for chimeric antigen receptor (CAR) T-cell therapy, ideally at relapse and before the next treatment line, can expand access and improve outcomes, as multidisciplinary collaboration makes this...
A panel of experts determined...
11/14/2025
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022
Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Conference Coverage
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
12/08/2021
Janelle Bradley
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways
News
HCRU and End-of-Life Outcomes Among Patients Receiving CAR-T Therapy
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access
03/15/2021
Praveen Ramakrishnan Geethakumari, MD; Ankit J. Kansagra, MD; Dheepthi Perumal Ramasamy, BS; Binod Dhakal, MD
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan Geethakumari, MD, and colleagues address clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.
Praveen Ramakrishnan...
03/15/2021
Journal of Clinical Pathways
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
12/20/2020
12/20/2020
Journal of Clinical Pathways

Expert Insights

Ajeet Gajra, MD, FACS
Videos
Barriers to CAR-T Therapy Utilization Among Community Hematologists/Oncologists in the US
01/19/2022
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses findings from a study analyzing the utilization of and barriers to CAR-T therapies by community hematologists/oncologists in the United States, discussing deterrents such as cost and lack of support.
Ajeet Gajra, MD, FACS, discusses...
01/19/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Editor Insights
CAR-T Reimbursement Levels Set by CMS, So Where Should Patients Be Treated?
04/19/2018
Winston Wong, PharmD
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to be provided on an outpatient basis, thus placing financial burden upon the patient, or will they allow the oncologist or facility to use their discretion as to where the infusion will take place?
Will payers push for services to...
04/19/2018
Journal of Clinical Pathways
Guest Blog
Why Payers, Other Stakeholders Should Remain Optimistic About CAR-T Therapies
03/15/2018
Bruce A. Feinberg, DO; Chadi Nabhan, MD, MBA, FACP
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi Nabhan, MD, MBA, FACP, contend that collaboration between payers and other stakeholders will help amend the concerns regarding newly approved CAR-T therapies.
Bruce A Feinberg, DO, and Chadi...
03/15/2018
Journal of Clinical Pathways
Editor Insights
The CAR-T Breakthrough: More Than Just Another Treatment Option
02/02/2018
Winston Wong, PharmD
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill an unmet need in hematologic malignancies, they are not without risk and cost burdens, according to Winston Wong, PharmD.
While CAR T-cell therapies fill...
02/02/2018
Journal of Clinical Pathways
Headshot of Joe DePinto
Interview
Expanding Cell and Gene Therapy Adoption in Oncology Care
11/03/2026
Joe DePinto
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto...
11/03/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 2
10/21/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu...
10/21/2026
Journal of Clinical Pathways
Rob Helton
Interview
Embedding Genomic Data, Clinical Guidelines, and Payer Requirements Into Community Oncology Workflows
10/19/2026
Rob Helton, DPT
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how...
10/19/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
Improving Therapy Options and Patient Experiences in NSCLC: Part 1
10/13/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu...
10/13/2026
Journal of Clinical Pathways
Gary Simmons, DO, MSHA
Interview
Expanding CAR T-Cell Therapy Access in Community Oncology
09/29/2026
Gary L. Simmons, DO
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA,...
09/29/2026
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways

Newsfeed

News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
News
High Tumor Mutational Burden Predicts CAR-T Outcomes in LBCL, ASH 2025 Study Finds
12/05/2025
Juliet Gallagher
A new analysis presented at ASH 2025 identifies high tumor mutational burden as a clinically meaningful biomarker of negative outcomes following CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL). Using...
A new analysis presented at ASH 2025 identifies high tumor mutational burden as a clinically meaningful biomarker of negative outcomes following CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma (LBCL). Using...
A new analysis presented at ASH...
12/05/2025
Journal of Clinical Pathways
News
Expanding Access to CAR T-Cell Therapy Through Early Referral and Broader Eligibility
11/14/2025
Lisa Kuhns, PhD, MD
A panel of experts determined that early referral for chimeric antigen receptor (CAR) T-cell therapy, ideally at relapse and before the next treatment line, can expand access and improve outcomes, as multidisciplinary collaboration makes this...
A panel of experts determined that early referral for chimeric antigen receptor (CAR) T-cell therapy, ideally at relapse and before the next treatment line, can expand access and improve outcomes, as multidisciplinary collaboration makes this...
A panel of experts determined...
11/14/2025
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022
Katie Herman
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
News
HCRU and End-of-Life Outcomes Among Patients Receiving CAR-T Therapy
08/05/2021
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.
Findings from a recent study...
08/05/2021
Journal of Clinical Pathways
News
Real-World CAR-T Therapy Toxicity in Patients With DLBCL
11/11/2020
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring real-world experience and data are necessary and will help define and refine management of toxicities unique to CAR-T therapy.
More studies exploring...
11/11/2020
Journal of Clinical Pathways
News
Insurance Restrictions and High Costs Limit Blood Cancer Treatment Access
10/14/2026
Grace Taylor, MS, MA
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that...
10/14/2026
Journal of Clinical Pathways
News
EOM Lung Patient Pilot Associated With Reduced Emergency Care Utilization
10/09/2026
Rebecca Amrick
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model...
10/09/2026
Journal of Clinical Pathways
News
MYLUNG Study Links Timely Biomarker Testing to Improved Outcomes in mNSCLC
09/29/2026
Rebecca Amrick
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study...
09/29/2026
Journal of Clinical Pathways
News
Comprehensive Molecular Profiling Linked to Improved Survival in NSCLC
09/28/2026
Grace Taylor, MS, MA
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive...
09/28/2026
Journal of Clinical Pathways
News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
Enhanced Financial Assistance Associated With Improved Radiotherapy Completion
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
Molecular Testing Improves Survival Outcomes for Patients With Endometrial Cancer, Study Finds
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways
News
Rituximab Biosimilars Demonstrate Clinical Efficiency and Significant Cost Savings Among Patients With NHL and CLL
08/31/2026
Rebecca Amrick
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab...
08/31/2026
Journal of Clinical Pathways
News
Initiation of Bispecific Antibodies Associated With High Care Costs for Patients With MM
08/24/2026
Rebecca Amrick
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer...
08/24/2026
Journal of Clinical Pathways
News
Cytopenia Associated With Worse Survival Outcomes in Patients With Myelofibrosis
08/17/2026
Rebecca Amrick
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence...
08/17/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use